For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | |||
|---|---|---|---|---|
| Research and development | 22,889 | |||
| General and administrative | 5,020 | |||
| Total operating expenses | 27,909 | |||
| Loss from operations | -27,909 | |||
| Interest income | 1,125 | |||
| Interest expense | 98 | |||
| Other income (expense) | 13 | |||
| Total other income | 1,040 | |||
| Net loss | -26,869 | |||
| Basic EPS | -21.83 | |||
| Diluted EPS | -21.83 | |||
| Basic Average Shares | 1,230,698 | |||
| Diluted Average Shares | 1,230,698 | |||
Avalyn Pharma Inc. (AVLN)
Avalyn Pharma Inc. (AVLN)